TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05494593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELAPRASE
Description: Participants will receive 0.5 milligram per kilogram (mg/kg) of body weight of ELAPRASE, intravenous, infusion for 104 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants will receive 375 milligram per square meter per dose (mg/m\^2/dose) of intravenous rituximab weekly for 4 weeks in 5-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Participants will receive 0.4 mg/kg of methotrexate by mouth (PO) 3 times per week for 5 weeks in each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Immunoglobulin (IVIG)
Description: Participants will receive 500 mg/kg of IVIG every 4 weeks in 5-week cycle.
Study: NCT06411808

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory-Adapted Dental Environment
Description: The Sensory-Adapted Dental Environment (SADE) involves altering the dental setting to reduce sensory stimuli that can cause discomfort or anxiety in children with sensory processing disorders. This includes the use of controlled lighting, ambient sounds, and non-threatening tools to create a calming atmosphere conducive to positive dental experiences.
Study: NCT04958967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furmonertinib 240mg
Description: treated subjects will receive Furmonertinib 240mg/day
Study: NCT05148962

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GRT-R910
Description: Injection administered intramuscularly
Study: NCT04958967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furmonertinib 160mg
Description: treated subjects will receive Furmonertinib 160mg/day
Study: NCT05148962

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GRT-R910
Description: Injection administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GRT-R910
Description: Injection administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GRT-R910
Description: Injection administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GRT-R910
Description: Injection administered intramuscularly
Study: NCT04809506

Intervention type: BIOLOGICAL
Intervention: additional blood samples
Description: 2 additional blood samples (2 x 7ml) at every visit
Study: NCT06055790

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-Fluciclovine (Axumin) PET/CT
Description: PET/CT protocol:~All patients will be instructed to fast for 4 hr. prior to the scan. CT imaging of the head will be performed using GE Discovery MI Digital PET/CT (Boston, Massachusetts) prior to the injection of 18F-fluciclovine. While the patient is in a supine position on the PET table, 5 mCi (185 MBq) of 18F-fluciclovine will be administrated intravenously, followed by a saline flush. At the time of the injection, a continuous dynamic PET images lasting 60 min will be performed using 3D-dynamic and list-mode acquisition: 2.0 mm slice thickness, number of frames(f) x time in seconds(s) and minutes(m) of: 4f x 15s, 4f x 30s, 6f x 2m, 5f x 3m, and 6f x 5m. PET images at 0-5 (flow), 15-25 (early), 25-35 (mid), 45-60 min (delayed) post-injection will be reconstructed using Qclear 500 and OSEM iterative reconstruction with TOF (VPFX): 8 iterations, 5 subsets, 440 image matrix, 4 mm Gaussian filter, TOF. \[24, 27\].
Study: NCT04903730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AER-901 Solution for Nebulization
Description: Part A: participants will be enrolled into 1 of up to 5 sequential cohorts (A1 to A5). Inhaled AER-901 doses of 5, 10, 20, 40, and 80mg are planned.~Part B: participants will be enrolled into 1 of up to 3 cohorts (B1 to B3).~Cohorts B2 and B3 will commence following Part D of the study and following SRC review of safety, tolerability, and PK data. A decision to dose with either a propylene glycol formulation or a sterile water formulation will be made by the SRC at the time of the review of the Part D data.~Part D has a three-part design (Treatment Periods 1 \& 2 separated by a Washout period) and will compare placebo to a single-dose of AER-901 (5 mg/mL QD) followed by two doses of AER-901.~Each cohort will consist of 8 participants (6 receiving AER 901 and 2 receiving placebo).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.45% sterile saline for injection delivered via the FOX MOBILE device.
Study: NCT05908253

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: sham neurofeedback
Description: Both neural activity and accuracy of behavioral responses will be evaluated before and after a closed-loop sham neurofeedback protocol.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: nonadaptive neurofeedback
Description: Both neural activity and accuracy of behavioral responses will be evaluated before and after a closed-loop nonadaptive neurofeedback protocol. In this method, the stimuli is changed using the upcoming neural activity and an open-loop attention model of the corresponding human subject.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: adaptive neurofeedback
Description: Both neural activity and accuracy of behavioral responses will be evaluated before and after a closed-loop adaptive neurofeedback protocol. In this method, the stimuli is changed using the upcoming neural activity and an adaptive algorithm.
Study: NCT05785377

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-Neostigmine
Description: 20 mL bupivacaine 0.25% plus 1 mL Neostigmine (500 mcg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: 20 mL bupivacaine 0.25% plus 1 mL normal saline 0.9%
Study: NCT04638634

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL760
Description: An Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL760
Description: An Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin
Study: NCT05180500

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Q-Griffithsin
Description: Q-Griffithsin is derived from Griffithsin (GRFT) which is a non-glycosylated protein consisting of 121 amino acids. Q-GRFT contains a single amino acid substitution, M78Q variant, resistant to oxidation yet maintains the parent molecule's pharmacological profile.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A matched vehicle solution manufactured and dispensed in same applicators as the active comparator.
Study: NCT06167200

Intervention type: OTHER
Intervention: No intervention, study is observational
Description: No intervention, study is observational
Study: NCT03691480

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: simple exsufflation
Description: simple exsufflation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fuhrman catheter and ambulatory care
Description: Fuhrman catheter and ambulatory care
Study: NCT06438497

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIRS with f-UAS, lateral position
Description: In this intervention, patients were placed on operating table in lateral position. The coronal plane of the patient body was perpendicular to the operating table. The upper limbs were extended and fxed with brackets. A f-UAS is placed under the pelvi-ureteric junction (PUJ) in RIRS. The tip of the UAS has good flexibility and deformability. It can passively bend with the bending of the flexible ureteroscope (f-URS).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIRS with f-UAS, lithotomy position
Description: In this intervention, patients were placed on operating table in lithotomy position. This position is common and standard. A f-UAS is placed under the pelvi-ureteric junction (PUJ) in RIRS. The tip of the UAS has good flexibility and deformability. It can passively bend with the bending of the flexible ureteroscope (f-URS).
Study: NCT04791176

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: concurrent lenvatinib and Radiotherapy, followed lenvatinib maintenance
Description: Radiotherapy with IMRT or VMAT with 40-60Gy/20-30f; Concurrent Lenvatinib 12mg/day (for patients≥60 kg) or 8 mg/day (for patients\<60kg ) qd po. (Note: Levatinib can be given to patients in four weeks before Radiotherapy is applied, so that it can control disease during waiting for Radiotherapy). Maintenance Lenvatinib 12mg/day (for patients≥60 kg) or 8 mg/day (for patients\<60kg ) qd po until disease progress or unacceptable adverse events; six months is recommended but not mandatory.
Study: NCT06438497

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIRS with traditional UAS, lateral position
Description: In this intervention, patients were placed on operating table in lateral position. The coronal plane of the patient body was perpendicular to the operating table. The upper limbs were extended and fxed with brackets. A traditional UAS is placed under the pelvi-ureteric junction (PUJ) in RIRS.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RIRS with traditional UAS, lithotomy position
Description: In this intervention, patients were placed on operating table in lithotomy position. This position is common and standard. A traditional UAS is placed under the pelvi-ureteric junction (PUJ) in RIRS.
Study: NCT06470620

Intervention type: DIAGNOSTIC_TEST
Intervention: pelvic floor muscle assessment
Description: no intervention will be performed - several diagnostic assessments tools

Intervention type: DIAGNOSTIC_TEST
Intervention: pelvic floor muscle assessment
Description: no intervention will be performed - several diagnostic assessments tools
Study: NCT05775380

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone 45 mg
Description: We investigated the role of pioglitazone hydrochloride 45mg/day for five days in patients admitted for coronary artery bypass grafting (CABG) in order to investigate vascular SPhk1 expression, vascular transcriptome and proteome remodeling, as well as S1P content in HDL
Study: NCT05925439

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tuohy needle group
Description: Ultrasound-guided S1 transforaminal epidural block with Touhy needle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Quincke needle group
Description: Ultrasound-guided S1 transforaminal epidural block with Quincke needle
Study: NCT06600776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultra Rapid Lispro (URLi)
Description: Dosage Form:~Subcutaneous insulin infusion~Dosage:~Based on individual carbohydrate counting, adjusted using the MiniMed 780G hybrid closed-loop system.~Frequency:~Administered at mealtime (premeal) during one phase and immediately after meals (postmeal) during the other phase.~Duration:~Each intervention phase lasts up to 4 weeks.~Arm or Group/Intervention Cross-Reference:~Both interventions (mealtime and postmeal dosing) are applied to the single arm of the study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin pump with continuous glucose monitoring (CGM)
Description: The insulin pump with continuous glucose monitoring (CGM) system is used by patients with Type 1 Diabetes Mellitus (T1DM) as part of their regular treatment regimen. This system combines an insulin pump with real-time glucose monitoring, adjusting basal insulin delivery every 5 minutes based on continuous glucose data. In this study, participants are already using the system before the trial begins. The research does not examine the effect of the CGM itself but rather focuses on the timing of insulin bolus delivery (mealtime vs. postmeal) using their existing treatment system.~Frequency:~The system delivers basal insulin continuously and requires the patient to manually deliver bolus doses at mealtime (premeal) or postmeal, depending on the study phase.~Duration:~The device is used continuously throughout the entire study period, with each intervention phase (premeal vs. postmeal dosing) lasting up to 4 weeks.~Arm or Group/Intervention Cross-Reference:~This device will be us
Study: NCT06139185

Intervention type: OTHER
Intervention: Data collection
Description: Data collection

Intervention type: OTHER
Intervention: Data collection
Description: Data collection
Study: NCT05202210

Intervention type: BIOLOGICAL
Intervention: blood and urine sampling
Description: extra sample of blood and urine will be collected
Study: NCT05945095

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gum chewing group
Description: The mothers in the experimental group, on the other hand, will chew sugar-free gum for at least 15 minutes, starting from the second hour after the surgery.
Study: NCT05808985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium butyrate
Description: Take butyric acid (sodium butylate 600mg 2 tablets, BodyBio⒭, per day)
Study: NCT06464627

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: 16 weeks
Study: NCT05670444

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: kelavit
Description: The treatment group received two pills in the morning containing Vit C Vit D zinc and minerals and one pill of 2 mg of melatonin in the evening

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: kelavit
Description: The treatment group received two pills in the morning containing Vit C Vit D zinc and minerals and one pill of 2 mg of melatonin in the evening
Study: NCT05847608

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3
Description: Daily consumption of 500 mg DHA and 750 mg EPA in liquid form

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oleic Acid, Linoleic Acid
Study: NCT05398107

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Building Emotion Awareness and Mental Health (BEAM)
Description: The BEAM Program is based on best-practices in telehealth and science-based program design aimed at promoting maternal mental health and supportive parenting. The BEAM Program app is hosted on the University of Manitoba secure servers and is designed/managed by Tactica Interactive. The weekly group telehealth sessions will be led by clinical coaches (a mental health professional or Doctoral-Level Clinical Psychology Student) and will use the secure videoconferencing platform Zoom (Healthcare license). Parent coaches will be mothers who have recently participated in a prior iteration of the BEAM program. Parent coaches will engage with participants on the community peer support forum and will also attend weekly telehealth sessions. The therapeutic aims of the BEAM program are to improve symptoms of anxiety and depression as well as parenting skills, and will emphasize self-compassion, effective communication practices, and social support networks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control: MoodMission
Description: MoodMission will be used as our Standard of Care control group. MoodMission is an app based on CBT principles which creates tailored missions for mothers. These missions are based on self-reported mood and are aimed to improve mental health symptoms.
Study: NCT06440928

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobilization
Description: mobilization and exercise to be applied to patients with chronic lateral epicondylitis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard treatment
Description: standard treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard treatment
Description: standard treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard treatment
Description: standard treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: deep friction
Description: deep friction
Study: NCT03429413

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Protect Me 4 Application + External Quality Improvement Support
Description: Participants will be asked to interact with the Protect Me 4 application, using an iPad tablet. During the implementation period (months 4-6), intervention clinics will receive the Protect Me 4 app and External Quality Improvement Support (practice facilitation and external and internal provider peer opinion leaders and provider incentives). Providers from intervention clinics will complete audit and feedback reports to assess HPV vaccination rates with the assistance of the practice facilitator. Providers at the intervention clinic will complete a pre-intervention survey to obtain background information (demographics, approximate HPV vaccination rates, comfort with the use of technology etc.)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Protect Me 4 Application + External Quality Improvement Support
Description: Participants will be asked to interact with the Protect Me 4 application, using an iPad tablet. During the implementation period (months 4-6), intervention clinics will receive the Protect Me 4 app and External Quality Improvement Support (practice facilitation and external and internal provider peer opinion leaders and provider incentives). Providers from intervention clinics will complete audit and feedback reports to assess HPV vaccination rates with the assistance of the practice facilitator. Providers at the intervention clinic will complete a pre-intervention survey to obtain background information (demographics, approximate HPV vaccination rates, comfort with the use of technology etc.)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Protect Me 4 Application Alone
Description: During the maintenance period (months 7-9), intervention clinics will receive Protect Me 4 without external support (practice facilitation and external provider peer opinion leaders). Providers from intervention clinics will complete audit and feedback reports to assess HPV vaccination rates without the assistance of the practice facilitator. Providers at the intervention clinic will complete a post-intervention survey to gain provider feedback regarding the feasibility of Protect Me 4 and changes in perceptions regarding the use of technology.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Protect Me 4 Application Alone
Description: During the maintenance period (months 7-9), intervention clinics will receive Protect Me 4 without external support (practice facilitation and external provider peer opinion leaders). Providers from intervention clinics will complete audit and feedback reports to assess HPV vaccination rates without the assistance of the practice facilitator. Providers at the intervention clinic will complete a post-intervention survey to gain provider feedback regarding the feasibility of Protect Me 4 and changes in perceptions regarding the use of technology.
Study: NCT04866576

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Q CAN PLUS
Description: Active powder with fermented soy, 2 pouches per day, each pouch contains 12-15 gms of fermented soy

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin powder with Whey protein and flavor (provided by BESO Biological Research, Inc.)
Study: NCT05815966

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The effect of emotion recognition and empathy focused education program
Description: Emotion recognition and empathy-oriented education program is a group-based, interactive program that includes techniques such as vision development, brainstorming, painting and drawing, recital, role-playing, gamification and information notes, which requires the active participation of children. Within the program; There are trainings aimed at establishing bilateral relations, gaining in-group commitment, expressing emotions comfortably, feeling that they are not alone, and learning new resources that will make them feel good when they feel bad.~The aims of education; children,
Study: NCT05131763

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKG2D-based CAR T-cells
Description: Autologous genetically modified anti-NKG2DLs CAR transduced T cells
Study: NCT06466343

Intervention type: PROCEDURE
Group type: OTHER
Intervention: hysteroscopic resection of lower edge of cesarean scar niche
Description: Operative hysteroscopy will be used for surgical treatment in the cases. Hysteroscopic management of niche will be done according to the following steps: Operative procedure will be done postmenstrual, cervical preparation will be done by giving the patients misoprostol (misotac®) 400mcg two hours preoperative. Surgically, operative resectoscope (KARL STORZ, Germany,27 Fr gauge) will be inserted into the uterine cavity after cervical dilatation by Hegar uterine dilator up to 8. Distilled water will be used as distension media. Using a resectoscope, the lower edge of the niche will be trimmed, the base will be coagulated by using monopolar cutting current at 30-50 MHz.~The resected parts will be submitted together as one sampled specimen in one container of formaldehyde 30% (dissolved 800 ml water and 200 ml formaldehyde)
Study: NCT05363202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate Inhalation Aerosol 44 mcg
Description: Dosage Form: Metered dose Inhalation Aerosol Dosage Frequency 44 mcg (two inhalations; twice daily (i.e. morning \& evening approximately. 12 h apart, Mode of Administration: Oral inhalation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FLOVENT HFA 44 mcg
Description: Dosage Form: Metered dose Inhalation Aerosol Dosage Frequency 44 mcg (two inhalations; twice daily (i.e. morning \& evening approximately. 12 h apart, Mode of Administration: Oral inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo inhaler
Description: Dosage Form: Metered dose Inhalation Aerosol Dosage Frequency 44 mcg (two inhalations; twice daily (i.e. morning \& evening approximately. 12 h apart, Mode of Administration: Oral inhalation
Study: NCT06729866

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electrogram guided pulse field ablation
Description: In persistent atrial fibrillation patients, traget electrogram was mapped firstly , pulse field ablation of pulmonary veins, posterior wall of left atrium and target electrogram was ablated, until the atrial fibrillation converted to sinus rythm or stable atrial tachycardia. The mapping and ablation procedure was repeated until AF terminated or no target electrogram was found.
Study: NCT06728176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT1988
Description: Active Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT1988
Description: Active Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT1988
Description: Active Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT1988
Description: Active Drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT06728423

Intervention type: OTHER
Group type: OTHER
Intervention: Temporary target during an anaerobic training session
Description: Temporary target during an anaerobic training session

Intervention type: OTHER
Group type: OTHER
Intervention: SmartGuard during an anaerobic training session
Description: SmartGuard during an anaerobic training session